Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. CLPT
CLPT logo

CLPT Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
19.410
Open
18.650
VWAP
18.72
Vol
599.06K
Mkt Cap
561.40M
Low
18.030
Amount
11.21M
EV/EBITDA(TTM)
--
Total Shares
29.99M
EV
575.46M
EV/OCF(TTM)
--
P/S(TTM)
13.26
ClearPoint Neuro, Inc. is a commercial-stage medical device company that develops and commercializes integrated systems used in minimally invasive neurosurgical procedures in the brain. The Company provides clinical products and preclinical development services for controlled drug and device delivery. Its business consists of two components: a business providing medical devices for neurosurgical applications, and a business focused on partnerships in the biologics and drug delivery space. Its primary medical device product, the ClearPoint system, is an integrated system comprised of hardware components, disposable components, and intuitive, menu-driven software. The primary applications for the ClearPoint system are to target and guide the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, and the infusion of pharmaceuticals into the brain. It provides consulting services to its pharmaceutical and other medical technology partners.
Show More

Events Timeline

(ET)
2026-06-17
09:30:00
ClearPoint Neuro Shares Rise 32% to $17.66
select
2026-05-27 (ET)
2026-05-27
16:40:00
ClearPoint Neuro Enters Focused Ultrasound Market
select
2026-05-13 (ET)
2026-05-13
17:30:00
ClearPoint Neuro Receives CE Mark for Velocity Alpha MR Surgical Drill System
select
2026-05-13
17:00:00
Company Expects IRRAS Acquisition to Reduce Cash Burn
select
2026-05-13
16:50:00
Company Reports Q1 Revenue of $12.1M
select
2026-04-22 (ET)
2026-04-22
17:10:00
ClearPoint Neuro Completes First Procedure with Velocity Alpha MR Surgical Drill
select
2026-04-20 (ET)
2026-04-20
16:20:00
ClearPoint Neuro Receives Medical Device License from Health Canada
select

News

NASDAQ.COM
2.0
06-18NASDAQ.COM
uniQure Shares Surge After FDA Softens Stance on Gene Therapy
  • FDA Policy Shift: uniQure N.V. (QURE) shares surged 78.44% to $48.16 after the FDA accepted the 3-year analysis from its Phase I/II study as the primary basis for a Biologics License Application for AMT-130 in Huntington's disease, marking a significant regulatory milestone.
  • Positive Cancer Vaccine Responses: Elicio Therapeutics Inc. (ELTX) reported that three patients in its Phase 2 AMPLIFY-7P study showed excellent responses to the experimental vaccine ELI-002 7P, leading to a 70.65% stock increase to $4.71, indicating potential for enhanced immunotherapy effectiveness.
  • Key Company Developments: Lunai Bioworks (LNAI) saw its shares rise 40.06% to $4.00 as the CEO highlighted significant advancements, including a U.S. government defense contract and the development of an AI-driven precision neurology pipeline, positioning the company strategically in biotech and national security.
  • Patent Application Boost: Polyrizon Ltd. (PLRZ) shares increased by 15.55% to $13.23 following the publication of a U.S. patent application for its nasal drug delivery technology, showcasing its innovative capabilities in the biotech sector and potential market impact.
Newsfilter
8.5
06-17Newsfilter
NeOnc Technologies Secures International Drug Authorization for NEO212
  • International Drug Authorization: NeOnc Technologies has secured Investigational New Drug authorization for NEO212 from the Abu Dhabi Department of Health, marking a significant milestone in neuro-oncology and expected to accelerate its global market expansion.
  • Clinical Trial Progress: The Phase 2a study for NEO100 has achieved full enrollment, with preliminary data indicating approximately 24% tumor remission in recurrent glioblastoma patients, showcasing the potential market value of this therapy.
  • Insider Investment Confidence: CEO Amir Heshmatpour has personally invested over $500,000 recently, reflecting strong management confidence in the company's future, with total insider purchases nearing $1 million over the past year.
  • Financial Support: NeOnc Technologies has access to a $75 million at-the-market facility and a $10 million line of credit, providing robust financial backing for advancing multiple clinical programs.
seekingalpha
9.5
05-14seekingalpha
ClearPoint Neuro Reports Record Q1 2026 Revenue Amid Integration Progress
  • Record Revenue: ClearPoint Neuro achieved a record revenue of $12.1 million in Q1 2026, representing a 43% year-over-year increase, with organic device growth of 25%, indicating strong performance in the neurosurgery navigation market and potential for increased market share.
  • Acquisition Integration Progress: The majority of post-merger integration costs from the IRRAS acquisition were completed in Q1, with management stating that significant revenue and cost synergies will continue, and operational cash burn is expected to decrease in the coming quarters, enhancing financial stability.
  • FDA New Product Approval: The company received FDA clearance for the Velocity Alpha MR high-speed surgical drill system and CE marking in Europe, marking an expansion of its product line and expected to provide strong support for future revenue growth.
  • 2026 Outlook: Management expects revenue for 2026 to be in the range of $52 million to $56 million, with all four business segments anticipated to grow in double digits, reflecting confidence in future market demand.
seekingalpha
9.5
05-13seekingalpha
ClearPoint Neuro Q1 Earnings Beat Expectations Despite EPS Miss
  • Earnings Highlights: ClearPoint Neuro reported a Q1 GAAP EPS of -$0.32, missing estimates by $0.05, yet revenue reached $12.13 million, a 42.9% year-over-year increase, surpassing expectations by $0.16 million, indicating strong growth potential in the market.
  • Cash Flow Status: As of March 31, 2026, the company had cash and cash equivalents totaling $35.6 million, down from $45.9 million at December 31, 2025, primarily due to $8.0 million in cash used for operating activities and $2.0 million in tax payments related to equity awards, reflecting pressure on cash management.
  • Acquisition Synergies: The company anticipates that cost synergies from the acquisition of IRRAS will contribute to a reduction in cash burn in the second half of 2026, believing that asset integration could potentially be cash neutral for the full year 2027, demonstrating confidence in future financial health.
  • Business Outlook: ClearPoint Neuro estimates revenue for 2026 to be between $52.0 million and $56.0 million, below the analyst consensus of $53.3 million; nevertheless, the company's long-term outlook remains optimistic, showcasing its competitive position in the industry.
seekingalpha
9.5
05-12seekingalpha
ClearPoint Neuro Q1 Earnings Announcement Scheduled
  • Earnings Announcement Date: ClearPoint Neuro, Inc. is set to announce its Q1 earnings on May 13th after market close, with a consensus EPS estimate of -$0.27 and a revenue estimate of $11.97 million, indicating challenges in profitability.
  • Earnings Estimate Revisions: Over the past three months, there have been no upward revisions to EPS estimates, with two downward adjustments, while revenue estimates also saw no upward revisions and two downward changes, reflecting market caution regarding the company's short-term performance.
  • Long-Term Outlook: Despite facing temporary headwinds, ClearPoint Neuro has outlined a revenue target of $52 million to $56 million for 2026, demonstrating the company's commitment to advancing its growth strategy and integrating the IRRAS acquisition.
  • Market Reaction: The company's FY26 guidance fell below analysts' estimates, leading to a significant drop in stock price, highlighting investor concerns about the company's future performance.
moomoo
7.0
05-08moomoo
ClearPoint Neuro and UniQure Stocks Surge Following WSJ Report on Trump's Potential Plan to Dismiss FDA Commissioner Marty Makary
  • Company Overview: ClearPoint Neuro and Uniqure are involved in the biotechnology sector, focusing on innovative solutions in neurotechnology.

  • Market Reaction: Shares of ClearPoint Neuro have seen a significant increase following reports from the Wall Street Journal regarding potential changes in leadership at the FDA.

  • Leadership Changes: The reports suggest that former President Trump is considering firing FDA Commissioner Marty Makary, which has implications for regulatory processes in the biotech industry.

  • Investor Sentiment: The news has sparked interest among investors, leading to a spike in ClearPoint Neuro's stock prices as market participants react to the potential shifts in FDA oversight.

Wall Street analysts forecast CLPT stock price to rise
2 Analyst Rating
Wall Street analysts forecast CLPT stock price to rise
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.000
sliders
Low
28.00
Averages
29.00
High
30.00
Current: 0.000
sliders
Low
28.00
Averages
29.00
High
30.00
B. Riley
Anderson Schock
Buy
maintain
$20 -> $30
AI Analysis
2026-06-18
Reason
B. Riley
Anderson Schock
Price Target
$20 -> $30
AI Analysis
2026-06-18
maintain
Buy
Reason
B. Riley analyst Anderson Schock raised the firm's price target on ClearPoint Neuro (CLPT) to $30 from $20 and keeps a Buy rating on the shares. ClearPoint Neuro is a direct beneficiary of uniQure's (QURE) FDA-supported path to accelerated approval for AMT-130 in Huntington's disease, with a planned Q3 BLA filing implying a potential mid-2027 approval timeline and the onset of commercial procedures, effectively converting prior regulatory optionality into a more visible and near-dated revenue opportunity for ClearPoint in 2H27, the analyst tells investors in a research note.
Stifel
Tom Stephan
Buy
initiated
$16
2026-05-08
Reason
Stifel
Tom Stephan
Price Target
$16
2026-05-08
initiated
Buy
Reason
Stifel analyst Tom Stephan resumed coverage of ClearPoint Neuro with a Buy rating and $16 price target. ClearPoint is well-positioned in the large neurological disorder market with its \"robust\" and \"differentiated\" neuro ecosystem that enables precise delivery of both drugs and devices, the analyst tells investors.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for CLPT
Unlock Now

Valuation Metrics

The current forward P/E ratio for Clearpoint Neuro Inc (CLPT.O) is 12.11, compared to its 5-year average forward P/E of -14.23. For a more detailed relative valuation and DCF analysis to assess Clearpoint Neuro Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-14.23
Current PE
12.11
Overvalued PE
-4.97
Undervalued PE
-23.48

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-21.03
Current EV/EBITDA
-13.69
Overvalued EV/EBITDA
-8.37
Undervalued EV/EBITDA
-33.68

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
9.59
Current PS
8.76
Overvalued PS
14.35
Undervalued PS
4.84

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

what if I have $5000 to invest
Intellectia · 90 candidates
Region: USPrice: >= $-100.00Ema 20: >= -100News Driver: Positive
Ticker
Name
Market Cap$
top bottom
ICCM logo
ICCM
Icecure Medical Ltd
17.96M
QURE logo
QURE
Uniqure NV
3.04B
FTHM logo
FTHM
Fathom Holdings Inc
36.39M
ALOT logo
ALOT
AstroNova Inc
219.65M
BIRD logo
BIRD
Allbirds Inc
48.26M
CLWT logo
CLWT
Euro Tech Holdings Company Ltd
11.64M
what stocks have have hit pivot bottom
Intellectia · 247 candidates
Rsi Category: moderate, oversoldMoving Average Relationship: PriceAboveMA5Month Price Change Pct: $-45.00 - $-1.00Support Resistance Relationship: PriceAroundSupportMonthly Average Dollar Volume: >= 150,000
Ticker
Name
Market Cap$
top bottom
LFCR logo
LFCR
Lifecore Biomedical Inc
149.91M
NG logo
NG
NovaGold Resources Inc
3.54B
GLDG logo
GLDG
GoldMining Inc
243.68M
CLPT logo
CLPT
Clearpoint Neuro Inc
282.10M
PZG logo
PZG
Paramount Gold Nevada Corp
137.45M
CANF logo
CANF
Can Fite Biopharma Ltd
6.59M
what are pre market low cap movers
Intellectia · 48 candidates
Market Cap: 30.00M - 3.00BRegion: USPrice: $0.30 - $30.00List Exchange: XNYS, XNAS, XASEPre Market Price Change: $3.00 - $100.00
Ticker
Name
Market Cap$
top bottom
IPSC logo
IPSC
Century Therapeutics Inc
459.90M
CBUS logo
CBUS
Cibus Inc
213.22M
GEOS logo
GEOS
Geospace Technologies Corp
130.55M
OBE logo
OBE
Obsidian Energy Ltd
573.46M
CGNT logo
CGNT
Cognyte Software Ltd
634.70M
VET logo
VET
Vermilion Energy Inc
1.73B

Whales Holding CLPT

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Clearpoint Neuro Inc (CLPT) stock price today?

The current price of CLPT is 18.72 USD — it has increased 0

What is Clearpoint Neuro Inc (CLPT)'s business?

ClearPoint Neuro, Inc. is a commercial-stage medical device company that develops and commercializes integrated systems used in minimally invasive neurosurgical procedures in the brain. The Company provides clinical products and preclinical development services for controlled drug and device delivery. Its business consists of two components: a business providing medical devices for neurosurgical applications, and a business focused on partnerships in the biologics and drug delivery space. Its primary medical device product, the ClearPoint system, is an integrated system comprised of hardware components, disposable components, and intuitive, menu-driven software. The primary applications for the ClearPoint system are to target and guide the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, and the infusion of pharmaceuticals into the brain. It provides consulting services to its pharmaceutical and other medical technology partners.

What is the price predicton of CLPT Stock?

Wall Street analysts forecast CLPT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CLPT is29.00 USD with a low forecast of 28.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Clearpoint Neuro Inc (CLPT)'s revenue for the last quarter?

Clearpoint Neuro Inc revenue for the last quarter amounts to 12.13M USD, increased 42.93

What is Clearpoint Neuro Inc (CLPT)'s earnings per share (EPS) for the last quarter?

Clearpoint Neuro Inc. EPS for the last quarter amounts to -0.32 USD, increased 45.45

How many employees does Clearpoint Neuro Inc (CLPT). have?

Clearpoint Neuro Inc (CLPT) has 172 emplpoyees as of July 05 2026.

What is Clearpoint Neuro Inc (CLPT) market cap?

Today CLPT has the market capitalization of 561.40M USD.